A Biotech Company Wants to Dilute Its Stock by 951% to Buy Crypto Instead of Funding Its Own Drug — Here's What That Means
(112 days ago) · 1 source · Summarized by CryptoBipto
A biotech company is asking shareholders to approve a massive stock dilution of 951% in order to accumulate an illiquid cryptocurrency token, rather than using the capital to fund its core pharmaceutical research and development. The move raises serious questions about corporate governance, fiduciary duty, and the growing trend of companies pivoting to crypto treasury strategies.
WHY IT MATTERS
Imagine you co-own a bakery with friends, and the manager suddenly says, 'Let's print 10 times more ownership shares and use the money to buy a rare collectible coin that's hard to sell — instead of buying a new oven.'
Read the full analysis with a CryptoBipto membership
Members read why every story matters and the full analysis behind it.
SOURCES
- Source
RELATED
Learn the concepts behind this
Clear explanations of the subjects this article touches, with every term defined.
